Methadone and buprenorphine treatment retention curbs risk of death

 after therapy per 1,000 years. For buprenorphine, overdose deaths increased in the first four weeks after stopping therapy and the overall death rate was 32 in the first four weeks and 10.9 in the remaining time without therapy. There was no significant difference between the first four weeks of therapy and the remaining time in the recovery center.

Two independent reviewers performed data extraction and assessed the quality of the study. Death rates in and just after therapy were combined across methadone and buprenorphine by random-effects meta-analysis.

The combined trend examination showed that comprehensively caused mortality decreased strongly over the first month of methadone therapy and decreased steadily 14 days after therapy.

Death rates from overall causes continued stable during induction and during the remaining time on buprenorphine treatment. Overdose deaths evolved similarly.

Advertisement

The study found that the death risk among opioid users in therapy is less than a third of that expected in the absence of opioid therapy. Buprenorphine maintenance therapy is most likely effective in reducing death, but quantification of averted deaths requires further study.

Ryan Beitler
Author: Ryan Beitler

An editor and contributor to Addiction Now, Ryan Beitler is a journalist, fiction writer, musician, and travel writer. He has written for Paste Magazine, OC Weekly, numerous addiction recovery publications, and his travel blog Our Little Blue Rock. He lives in Southern California. Contact Ryan at ryanrbeitler@gmail.com or ryanb@addictionnow.com.

Summary
 Methadone and buprenorphine treatment retention curbs risk of death
Article Name
Methadone and buprenorphine treatment retention curbs risk of death
Description
Retention in treatment is linked to significant reductions in risks of death and deadly overdoses among opioid dependents, a new study shows.
Author
Ryan Beitler
Publisher Name
Addiction Now